Business
Certara provides biosimulation science, software, and consulting services used in model-informed drug development for biopharma and biotech customers.
Certara turned biosimulation demand into higher FCF, but profit is still thin.
The read at a glance✓ Audited against SEC data
- Business mix — Biosimulation software and servicesNote
- Revenue — $418.8M, +8.7%OK
- Operating income — $21.0M from a lossOK
- Net loss — ($1.6M), much narrowerNote
- FCF — $94.6M, +19.9%OK
- Insiders — 1 purchase and 1 saleNote
- Accounting — Altman weak; Beneish clean; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as Certara, Inc. reports it. History and quarterly detail are in the app.
- Reportable$418.8M
Leadership changes
From Certara, Inc.'s own filings, the day they're filed.
- Faiz Mohammed · Chief Financial Officer · appointmenteff. 2026-07-15
- John E. Gallagher III · Chief Financial Officer · departureeff. 2026-06-11
- William F. Feehery · Chief Executive Officer · departureeff. 2026-01-01
Latest filings
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-17
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Certara, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.